why choose us

First received: August 15, 2022

Clinical Trial: A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cystic Fibrosis

Study Type: INTERVENTIONAL


Official Title: KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis

Brief Summary: This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Read more